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INTRODUCTION 
The most common plasmid-mediated P-lactamases in 
the Enterobacteriaceae are TEM-1, TEM-2 and S H V -  
1, which have a weak activity against first-generation 
cephalosporins. Neither oximino p-lactams, in partic- 
ular cefotaxime and cefiazidime, nor monobactams and 
carbapenems were hydrolyzed by TEM-1 or -2 or SHV 
P-lactamases until enzyme mutants emerged in the 
mid-1980s. 
Because of their greatly extended substrate range, 
these mutant enzymes were called extended-spectrum 
P-lactamases (ESBLs) [ 13. ESBLs were first recognized 
in Europe, in Germany [2] and in France [3,4], and 
have, since then, been reported around the world [5]. 
There has been a rapid increase in the number and 
variety of ESBLs and in the mechanisms that regulate 
their production and spread. 
Klebsiella pneumoniae is by far the most common 
species in which ESBLs have been recognized (75% of 
ESBL-producing strains). ESBLs have been detected in 
nearly all other species of Enterobacteriaceae, but occur 
much less frequently. Recent surveys of hospital isolates 
of K. pneumoniae in Europe indicate that 14% to 16% 
produce ESBLs, whereas a low frequency (<0.1%) is 
observed in Escherichia coli [6,7]. Reports of ESBLs in 
Proteus mirabilis have been relatively rare, perhaps because 
of the low frequency of plasmid acquisition, or of 
failure to detect enzyme production in this species [8]. 
ESBLs differ from the parent enzyme, either TEM 
or SHV penicillinases, by one to four amino acid 
changes which alter the substrate specificity and are 
predominantly located at positions 104, 164, 205, 237, 
238 and 240 (according to Ambler numbering). In 
recent years, there have been numerous reports of 
ESBLs from different parts of the world, with the 
TEM-type enzymes forming the largest group (more 
than 20 types), while the variety of ESBLs reported in 
the SHV family is limited (n=6). 
ESBLs derived &om TEM or SHV vary consider- 
ably according to the level of resistance they confer to 
cefotaxime (CTX), cehid ime (CAZ) and aztreonam 
(ATM). With the exception of CTX-l/TEM-3 and 
TEM-4, which confer resistance to approximately 
32 mg/L of cefotaxime, TEM derivatives are respons- 
ible for low or moderate MIC values (0.06 to 4 mg/L). 
MICs of ceftazidime are higher (4 to 512 mg/L) than 
those of cefotaxime. The MICs of aztreonam (0.1 to 
128 mg/L) are never higher than those of ceftazidime, 
except for TEM-22, which confers a higher MtC of 
aztreonam (128 mg/L) than that of ceftazidime 
(4 mg/L). SHV-2 to SHV-5 derivatives are more 
potent ESBLs, since they confer MICs 232 mg/L of 
cefotaxime, ceftazidime and aztreonam [5]. These 
enzymes have no detectable activity against cepha- 
mycins and carbapenems. 
All the SHV and TEM extended-spectrum deriva- 
tives are sensitive to the P-lactamase inhibitors 
clavulanate, sulbactam and tazobactam. Of the three 
inhibitors, clavulanate is the most effective, whereas 
sulbactam is only of marginal benefit, especially against 
strains producing enzymes of the SHV family. 
DETECTION 
The double disk synergy (DDS) test described by Jarlier 
et al. [9], based on synergy between P-lactamase 
inhibitors and cefotaxime, ceftazidime or aztreonam, 
enables the detection of ESBLs in strains misclassified 
as susceptible on the basis of standard interpretative 
criteria for the disk diffusion method. Disks of CTX, 
CAZ or ATM are placed around a disk of amoxicillin 
+ clavulanate (AMC) 30 mm apart (center to center). 
The DDS test is always positive with K. pneumoniae 
and E. coli strains producing an ESBL-enzyme (Figure 
1). Moreover, the presence of an ESBL is strongly 
suggested by high levels of resistance to penicillins and 
to first- and second-generation cephalosporins, except 
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Figure 1 
observed between FEP (cefepirne), CTX (cefotaxime), CAZ (cefiazidme), 
ATM (aztreonam) and AMC (co-amoxiclav) disks placed 30 mm apart. 
Bottom half-part: synergy is also detected by placing the &sks of CTX, CAZ 
and ATM around the disk of AMC 20 mm apart. No synergy is observed 
between AMC and the p-lactamase-resistant compound FOX (cefoxitine). 
DDS test with K. pneumoniae (TEM-3). Top half-part: synergy is 
cephamycins, and by frequently associated resistance to 
aminoglycosides (AAC-6'). 
False-negative results 
In ESBL-producing I? mirabilis, inhibition diameters of 
CTX, CAZ and ATM are >28 mm. These large 
diameters are often responsible for false-negative 
double disk synergy tests when the disks are placed as 
described (Figure 2A). A positive synergy test is 
observed (Figure 2B) when disks are further apart 
(40 mm center to center) or when the disks of CTX, 
CAZ and ATM are quartered in order to reduce their 
potency. 
In species such as Enterobacter cloacae hyperproduc- 
ing a cephalosporinase in addition to an ESBL, the high 
levels of resistance (MICs >32 mg/L) to CTX, CAZ 
and ATM are responsible for a false-negative synergy 
test (because of reduced zone diameters). Synergy can 
be detected by reducing the distance between the disks 
to 20 mm, or by a synergy test with a disk of cefepime 
or cefpirome which are less hydrolyzed than CTX, 
CAZ and ATM by the cephalosporinase (Figure 3). 
Non-specific positive results 
Certain species of Enterobacteriaceae produce a 
chromosomal p-lactamase which hydrolyzes third- 
generation cephalosporins and aztreonam when hyper- 
produced and which is inhibited by clavulanic acid. 
The DDS test may be positive in Klebsiella oxytoca, 
Citrobacter diversus, Proteus vulgaris, Proteus penneri, 
Kluyvera ascorbata and Serratia fonticola, even if the strain 
does not produce an ESBL. 
INTERPRETATION 
In some species, mainly I? mirabilis but also E. coli or 
Klebsiella producing certain TEM-derived ESBLs, low 
or moderate MIC values (MIC < lower breakpoint) 
are frequently observed with cefotaxime, ceftriaxone, 
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Figure 2 
not visible irrespective of the arrangement of the disks. (B) A synergy is 
observed between CTX, CAZ, ATM and AMC when the disks are placed 
further apart (40 mm). 
DDS test with I! mirubilis (TEM-3). (A) The synergy is slightly or 
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Figure 3 DDS test with E. aerogenes (TEM-24 and cephalosporinase). A 
synergy is observed only between FEP and AMC disks (top half-part) or 
between ATM and AMC when the disks are placed 20 mm apart (bottom 
half-part), 
aztreonam and the most recent cephalosporins cefe- 
pime or cefpirome. 
All these p-lactams are hydrolyzed by ESBL to 
various extents and, even if the level of resistance 
conferred is low, the strains must be classified as 
‘Intermediate’ to all third-generation cephalosporins, 
since it is not known if such isolates are clinically 
susceptible to these drugs. Morevoer, therapy with 
third generation cephalosporins could be responsible 
for the emergence of a resistant strain producing an 
ESBL enzyme with an additional mutation increasing 
the hydrolytic activity of the parent enzyme. 
In urinary tract infections, a therapeutic option is 
the use of a combination penicillin + P-lactamase 
inhibitor. Combination of a third-generation cephalo- 
sporin, such as cefotaxime, with sulbactam could also 
be of interest. 
In severe infections, the most potent p-lactams are 
the carbapenems that are highly resistant to the 
hydrolytic activity of all the TEM- and SHV-related 
P-lactamases. The 7-a-methoxy cephalosporins, such 
as cefoxitin, cefotetan and latamoxef, are often effective. 
Of these, cefotetan and latamoxef are the most active. 
However, cephamycins should be used with caution 
to treat infections caused by ESBL-producing K .  
pneumoniae because of the relative ease with which 
clinical strains decrease the expression of outer mem- 
brane proteins. 
References 
1. Philippon A, Labia R, Jacoby G. Extended-spectrum p- 
lactamases. Antimicrob Agents Chemother 1989; 33: 1131-6. 
2. Knothe A, Shah P, Kremery V, Antal M, Mitsuhashi S. 
Transferable resistance to cefotaxime, cefoxitin, cefamandole 
and cefuroxime in clinical isolates of Klebsiella pneumorriae and 
Serratia marcescens. Infection 1983; 11: 315-17. 
3. Brun-Buisson C, Legrand P, Philippon A, Montravers F, 
Ansquer M, Duval J. Transferable enzymatic resistance to 
third-generation cephalosporins during nosocomial outbreak 
of multiresistant Klebsiella pneumoniae. Lancet 1987; ii: 302-6. 
4. Sirot D, Sirot J, Labia R, Morand A, Courvalin P, Darfeuille- 
Michaud A. Transferable resistance to third-generation 
cephalosporins in clinical isolates of Klebsiella pneumoniae: 
identification of CTX-1, a novel p-lactamase. Antimicrob 
Agents Chemother 1987; 20: 323-33. 
5. Jacoby GA, Medeiros AM. More extended-spectrum p- 
lactamases. Antimicrob Agents Chemother 1991; 35: 1697- 
704. 
6. Sirot D, Goldstein FW, Soussy CJ, et al. Resistance to 
cefotaxime and seven other p-lactams in members of the 
S i r o t :  D e t e c t i o n  o f  e x t e n d e d - s p e c t r u m  p l a s m i d - m e d i a t e d  f i - l ac tamases  s39 
fandy Enterobacteriaceae: a 3-year survey in France. Antimicrob 
7. Goldstein Fw, Ptan Y, Rosato A, et al. Characterisation of 
ceftriaxone-resistant Enterobacteriaceae: a multicentre study in 
26 French hospitals. J Antimicrob Chemother 1993; 32: 
595-603. 
bacdles 1 gram ntgatif. La lettre de I’Infectiologue 1994; 5: 
9. Jarlier V, Nicolas MH, Fournier G, Phihppon A. Extended 
broad-spectrum P-lactamases conferring transferable resist- 
ance to newer p-lactam agents in Enterobacteriaceae: hospital 
prevalence and susceptibdity patterns. Rev Infect Dis 1988; 
Agents Chemother 1992; 36: 1677-81. 151-5. 
8. Nordmann P, Nass T, Labia R. Les nouvelles p-lactamases des 10: 867-78. 
